Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Medical Genetics · Hypermobile Ehlers-Danlos Syndrome

The Diagnostic Journey: How hEDS and HSD are Identified

At a Glance

hEDS is diagnosed clinically using generalized joint hypermobility, the 2017 criteria, and exclusion of other conditions; there is no confirmatory genetic test. Symptomatic hypermobility that does not meet all hEDS criteria may be diagnosed as HSD.

Diagnosing hypermobile Ehlers-Danlos Syndrome (hEDS) and Hypermobility Spectrum Disorders (HSD) changed significantly in 2017. Because there is currently no blood test or genetic test that can “prove” someone has hEDS, doctors use a strict set of clinical criteria—essentially a checklist of physical signs and medical history [1][2].

This process is designed to be rigorous. If you don’t meet every single requirement for hEDS, but have symptomatic hypermobility and have had other causes excluded, you may be diagnosed with HSD instead. It is important to remember that the management and the reality of your symptoms are often the same regardless of which label you receive [3].

Step 1: The Beighton Score (Criterion 1)

The first step is checking for Generalized Joint Hypermobility (GJH). Doctors use the Beighton Score, a 9-point exam that tests specific joints [4]:

  • Pinky Fingers: Can you bend them backward past 90 degrees? (1 point per side)
  • Thumbs: Can you push your thumb back to touch your forearm? (1 point per side)
  • Elbows: Do they hyperextend (bend backward) more than 10 degrees? (1 point per side)
  • Knees: Do they hyperextend more than 10 degrees? (1 point per side)
  • Spine: Can you put your palms flat on the floor without bending your knees? (1 point)

Age Matters

Because we naturally become stiffer as we age, the “passing” score changes [5]:

  • Children/Adolescents: Current pediatric frameworks generally use pediatric hypermobility categories and defer an hEDS label until biological maturity rather than applying the adult diagnosis simplistically to all children. When assessing generalized joint hypermobility, children usually require a score of 6 or higher [6].
  • Adults (up to age 50): Usually require a score of 5 or higher [7].
  • Adults (over age 50): Usually require a score of 4 or higher [5].

The 5-Part Questionnaire (5PQ)

If your score is exactly one point below the cutoff, your doctor may use a historical questionnaire. If you answer “yes” to at least two of these, it can count as evidence of historical hypermobility [8][7]:

  1. Can you now (or could you ever) place your hands flat on the floor without bending your knees?
  2. Can you now (or could you ever) bend your thumb to touch your forearm?
  3. As a child, did you amuse your friends by contorting your body or doing the splits?
  4. As a child or teenager, did your shoulder or kneecap dislocate on more than one occasion?
  5. Do you consider yourself “double-jointed”?

Step 2: Systemic Features and Family (Criterion 2)

To meet Criterion 2, you must satisfy two out of three of the following sub-categories [1]:

  • Feature A (Systemic Signs): You need at least 5 out of 12 specific signs that your connective tissue is affected elsewhere. These include unusually soft or velvety skin, mild skin stretchiness, unexplained stretch marks, certain types of hernias, or specific findings on a heart ultrasound (echocardiogram) like mitral valve prolapse [9][10].
  • Feature B (Family History): Having a parent, sibling, or child who independently meets the 2017 criteria for hEDS [11].
  • Feature C (Musculoskeletal Complications): You must have chronic pain in two or more limbs for at least 3 months, chronic widespread pain for at least three months, OR a history of recurrent joint dislocations or frank joint instability in the absence of trauma [3].

Step 3: Ruling Everything Else Out (Criterion 3)

The final step is making sure your symptoms aren’t better explained by something else. This is where Differential Diagnosis comes in [12]. Your doctor must confirm that you do not have:

  • Other types of EDS (like Classical or Vascular EDS).
  • Other heritable connective tissue disorders like Marfan Syndrome or Loeys-Dietz Syndrome [13][14].
  • Autoimmune or inflammatory conditions (like Rheumatoid Arthritis) that might cause your joint pain [12].

The Role of Genetic Testing

There is no genetic test for hEDS. If your doctor orders genetic testing, they are usually trying to rule OUT more rare and potentially serious conditions [15].

Testing is typically recommended if you have “red flags” such as [9][16]:

  • A family history of early aneurysms or organ ruptures.
  • Extremely fragile skin that tears easily or heals with “cigarette paper” scars.
  • Significant heart or blood vessel issues found on imaging.

If your genetic testing comes back negative, it does not confirm hEDS or HSD; it simply means the specific genetic conditions tested for are much less likely. hEDS remains a clinical diagnosis based on how your body looks and functions, made after other conditions have been appropriately excluded [17][18].

Common questions in this guide

How is hEDS diagnosed if there is no genetic test?
hEDS is diagnosed clinically by assessing generalized joint hypermobility, additional body-wide or musculoskeletal features, and family history, then ruling out other conditions. There is currently no blood test or genetic test that confirms hEDS.
What Beighton score is considered hypermobile?
Commonly used adult cutoffs are 5 or more points up to age 50 and 4 or more points after age 50. Children and adolescents are often assessed using pediatric frameworks, with a score of 6 or more commonly used for generalized joint hypermobility; clinicians also consider age, injuries, and stiff joints.
What happens if my Beighton score is one point below the cutoff?
A clinician may use the five-part questionnaire to look for hypermobility you had in the past. Answering yes to at least two questions can provide evidence of historical hypermobility and may support the assessment.
What is the difference between hEDS and HSD?
hEDS requires meeting all parts of the established clinical criteria after other explanations have been excluded. HSD may be diagnosed when a person has symptomatic hypermobility but does not meet every hEDS requirement, and symptoms and management can still be similar.
Does a negative genetic test rule out hEDS?
No. A negative genetic test does not confirm hEDS or HSD, but it can make certain other inherited connective tissue conditions less likely. hEDS remains a clinical diagnosis based on the person’s features, symptoms, and medical history.
When might someone with hypermobility need genetic testing?
A clinician may recommend genetic testing when there are warning signs for another inherited condition, such as a family history of early aneurysms or organ rupture, very fragile skin with unusual scars, or significant heart or blood vessel findings. The purpose is usually to evaluate alternatives to hEDS rather than to confirm hEDS itself.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on hypermobility syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can we go through the official 2017 hEDS checklist together to see exactly which 'Feature A' systemic signs I have?
  2. 2.What was my Beighton score today, and did you adjust the goal for my age or any joints that are stiff due to past injuries?
  3. 3.If I don't meet the full criteria for hEDS, would a diagnosis of Generalized Hypermobility Spectrum Disorder (G-HSD) change my access to physical therapy or other specialists?
  4. 4.Are there any 'red flag' symptoms in my history—like heart issues or severe bruising—that mean I should have genetic testing to rule out other conditions?
  5. 5.If my Beighton score was a '4' today, do my answers on the 5-part questionnaire suggest I have historical hypermobility that counts toward my diagnosis?

References

References (18)
  1. 1

    Hypermobile Ehlers-Danlos Syndrome: Diagnostic Challenges and the Role of Genetic Testing.

    Forghani I, See J, McGonigle WC

    Genes 2025; (16(5)) doi:10.3390/genes16050530.

    PMID: 40428350
  2. 2

    Complex Genetics and Regulatory Drivers of Hypermobile Ehlers-Danlos Syndrome: Insights from Genome-Wide Association Study Meta-analysis.

    Petrucci-Nelson T, Guilhaumou S, Berrandou TE, et al.

    medRxiv : the preprint server for health sciences 2025; doi:10.1101/2025.09.19.25336146.

    PMID: 41001447
  3. 3

    Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders.

    Yew KS, Kamps-Schmitt KA, Borge R

    American family physician 2021; (103(8)):481-492.

    PMID: 33856167
  4. 4

    Development and validation of self-reported line drawings of the modified Beighton score for the assessment of generalised joint hypermobility.

    Cooper DJ, Scammell BE, Batt ME, Palmer D

    BMC medical research methodology 2018; (18(1)):11 doi:10.1186/s12874-017-0464-8.

    PMID: 29343224
  5. 5

    Generalized Joint Hypermobility in Adults: A Systematic Review With Meta-Analysis to Identify Data-Driven Cut-offs Using the Beighton Score.

    Tofts L, Pacey V, Williams CM, et al.

    Arthritis care & research 2026; (78(8)):987-997 doi:10.1002/acr.70017.

    PMID: 41399207
  6. 6

    Pediatric joint hypermobility: a diagnostic framework and narrative review.

    Tofts LJ, Simmonds J, Schwartz SB, et al.

    Orphanet journal of rare diseases 2023; (18(1)):104 doi:10.1186/s13023-023-02717-2.

    PMID: 37143135
  7. 7

    Measurement properties of clinical assessment methods for classifying generalized joint hypermobility-A systematic review.

    Juul-Kristensen B, Schmedling K, Rombaut L, et al.

    American journal of medical genetics. Part C, Seminars in medical genetics 2017; (175(1)):116-147 doi:10.1002/ajmg.c.31540.

    PMID: 28306223
  8. 8

    Validity of the self-reported five-part questionnaire as an assessment of generalized joint hypermobility in early pregnancy.

    Schlager A, Ahlqvist K, Pingel R, et al.

    BMC musculoskeletal disorders 2020; (21(1)):514 doi:10.1186/s12891-020-03524-7.

    PMID: 32746889
  9. 9

    Ehlers-Danlos Syndromes and Related Disorders: Diagnostic Challenges and the Need for an Interdisciplinary Patient Care in Germany.

    Kernich N, Peters F, Schreml J, et al.

    Dermatology (Basel, Switzerland) 2025; (241(2)):124-132 doi:10.1159/000542026.

    PMID: 39657610
  10. 10

    Diagnosis and Management of Hypermobility Spectrum Disorders in Primary Care.

    Atwell K, Michael W, Dubey J, et al.

    Journal of the American Board of Family Medicine : JABFM 2021; (34(4)):838-848 doi:10.3122/jabfm.2021.04.200374.

    PMID: 34312277
  11. 11

    Prevalence of hypermobile Ehlers-Danlos syndrome in postural orthostatic tachycardia syndrome.

    Miller AJ, Stiles LE, Sheehan T, et al.

    Autonomic neuroscience : basic & clinical 2020; (224()):102637 doi:10.1016/j.autneu.2020.102637.

    PMID: 31954224
  12. 12

    Differential diagnosis and diagnostic flow chart of joint hypermobility syndrome/ehlers-danlos syndrome hypermobility type compared to other heritable connective tissue disorders.

    Colombi M, Dordoni C, Chiarelli N, Ritelli M

    American journal of medical genetics. Part C, Seminars in medical genetics 2015; (169C(1)):6-22 doi:10.1002/ajmg.c.31429.

    PMID: 25821090
  13. 13

    Differences in manifestations of Marfan syndrome, Ehlers-Danlos syndrome, and Loeys-Dietz syndrome.

    Meester JAN, Verstraeten A, Schepers D, et al.

    Annals of cardiothoracic surgery 2017; (6(6)):582-594 doi:10.21037/acs.2017.11.03.

    PMID: 29270370
  14. 14

    Marfan Syndrome: Enhanced Diagnostic Tools and Follow-up Management Strategies.

    Marelli S, Micaglio E, Taurino J, et al.

    Diagnostics (Basel, Switzerland) 2023; (13(13)) doi:10.3390/diagnostics13132284.

    PMID: 37443678
  15. 15

    Hypermobile Ehlers Danlos for the Primary Care Provider.

    White L, Procknow SS

    Missouri medicine 2024; (121(4)):289-296.

    PMID: 39575079
  16. 16

    Application of the 2017 criteria for vascular Ehlers-Danlos syndrome in 50 patients ascertained according to the Villefranche nosology.

    Ritelli M, Rovati C, Venturini M, et al.

    Clinical genetics 2020; (97(2)):287-295 doi:10.1111/cge.13653.

    PMID: 31600821
  17. 17

    Looking back and beyond the 2017 diagnostic criteria for hypermobile Ehlers-Danlos syndrome: A retrospective cross-sectional study from an Italian reference center.

    Ritelli M, Chiarelli N, Cinquina V, et al.

    American journal of medical genetics. Part A 2024; (194(2)):174-194 doi:10.1002/ajmg.a.63426.

    PMID: 37774134
  18. 18

    The role of gene encoding collagen secretion protein (SERPINH1) in the pathogenesis of a hypermobile type of Ehlers-Danlos syndrome.

    Junkiert-Czarnecka A, Pilarska-Deltow M, Bąk A, et al.

    Postepy dermatologii i alergologii 2023; (40(1)):102-106 doi:10.5114/ada.2022.124107.

    PMID: 36909907

This page is for informational purposes only and does not constitute medical advice or diagnose hEDS or HSD. Discuss your Beighton score, symptoms, and any need for genetic testing with a qualified clinician.